NO995433L - Protease-inhibitorer - Google Patents

Protease-inhibitorer

Info

Publication number
NO995433L
NO995433L NO995433A NO995433A NO995433L NO 995433 L NO995433 L NO 995433L NO 995433 A NO995433 A NO 995433A NO 995433 A NO995433 A NO 995433A NO 995433 L NO995433 L NO 995433L
Authority
NO
Norway
Prior art keywords
alkyl
het
6alkyl
6alkenyl
cycloalkyl
Prior art date
Application number
NO995433A
Other languages
English (en)
Norwegian (no)
Other versions
NO995433D0 (no
Inventor
Robert W Marquis
Yu Ru
Daniel Frank Veber
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of NO995433D0 publication Critical patent/NO995433D0/no
Publication of NO995433L publication Critical patent/NO995433L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/99—Enzyme inactivation by chemical treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
NO995433A 1997-05-08 1999-11-05 Protease-inhibitorer NO995433L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4686597P 1997-05-08 1997-05-08
PCT/US1998/009192 WO1998050534A1 (fr) 1997-05-08 1998-05-06 Inhibiteurs de proteases

Publications (2)

Publication Number Publication Date
NO995433D0 NO995433D0 (no) 1999-11-05
NO995433L true NO995433L (no) 1999-11-05

Family

ID=21945814

Family Applications (1)

Application Number Title Priority Date Filing Date
NO995433A NO995433L (no) 1997-05-08 1999-11-05 Protease-inhibitorer

Country Status (18)

Country Link
US (1) US6369077B1 (fr)
EP (1) EP0991753A4 (fr)
JP (1) JP2001525809A (fr)
KR (1) KR20010012316A (fr)
CN (1) CN1255162A (fr)
AU (1) AU7288598A (fr)
BR (1) BR9808502A (fr)
CA (1) CA2289010A1 (fr)
CO (1) CO4950617A1 (fr)
HU (1) HUP0001285A3 (fr)
IL (1) IL131661A0 (fr)
MA (1) MA26494A1 (fr)
NO (1) NO995433L (fr)
PE (1) PE73799A1 (fr)
PL (1) PL336625A1 (fr)
TR (1) TR199902752T2 (fr)
WO (1) WO1998050534A1 (fr)
ZA (1) ZA983843B (fr)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010032253A (ko) * 1997-11-18 2001-04-16 이타가키 히로시 시클릭 아민 유도체 및 그 약제로서의 용도
CO5150165A1 (es) * 1998-11-13 2002-04-29 Smithkline Beecham Plc Inhibidores de proteasa: tipo catepsina k
CO5180541A1 (es) * 1998-12-23 2002-07-30 Smithkline Beechman Corp Inhibidores de proteasa del tipo de 1,3-diaminocetonas con anillo de 8-14 miembros
WO2000069815A1 (fr) * 1999-05-13 2000-11-23 Teijin Limited Derives d'amines cycliques ureido-substituees et leur utilisation en tant que medicament
ATE277903T1 (de) 1999-05-14 2004-10-15 Bristol Myers Squibb Pharma Re Zyklische aminderivate und ihre verwendung
WO2000069432A1 (fr) 1999-05-18 2000-11-23 Teijin Limited Moyens de traitement et de prevention contre les maladies associees a des chimiokines
WO2001010439A1 (fr) * 1999-08-04 2001-02-15 Teijin Limited Antagonistes d'amine cyclique ccr3
US20070010509A1 (en) * 1999-12-08 2007-01-11 Tatsuki Shiota Cycloamine ccr5 receptor antagonists
WO2001045700A1 (fr) * 1999-12-21 2001-06-28 Smithkline Beecham Corporation Antagonistes des recepteurs de l'urotensine ii
IL151164A0 (en) 2000-03-06 2003-04-10 Acadia Pharm Inc Azacyclic compounds for use in the treatment of serotonin related diseases
EA005893B1 (ru) * 2000-03-21 2005-06-30 Смитклайн Бичам Корпорейшн Ингибиторы протеаз
US6362177B1 (en) 2000-05-16 2002-03-26 Teijin Limited Cyclic amine derivatives and their use as drugs
US8211916B2 (en) 2000-06-20 2012-07-03 Wayne State University N- and O-substituted 4-[2-(diphenylmethoxy)-ethyl]-1-[(phenyl)methyl]piperidine analogs and methods of treating CNS disorders therewith
US6995268B2 (en) 2000-06-20 2006-02-07 Wayne State University N- and O-substituted 4-[2-(diphenylmethoxy)-ethyl]-1- (phenyl) methyl) piperidine analogs and methods of treating CNS disorders therewith
US6395753B1 (en) * 2001-08-30 2002-05-28 Kowa Co., Ltd. Cyclic amine compounds and pharmaceutical composition containing the same
KR20100008799A (ko) 2001-12-28 2010-01-26 아카디아 파마슈티칼스 인코포레이티드 모노아민 수용체 조정자로서의 스피로아자사이클릭 화합물
US7282512B2 (en) 2002-01-17 2007-10-16 Smithkline Beecham Corporation Cycloalkyl ketoamides derivatives useful as cathepsin K inhibitors
US7253186B2 (en) 2002-06-24 2007-08-07 Carl-Magnus Andersson N-substituted piperidine derivatives as serotonin receptor agents
US7538222B2 (en) 2002-06-24 2009-05-26 Acadia Pharmaceuticals, Inc. N-substituted piperidine derivatives as serotonin receptor agents
MXPA04012893A (es) 2002-06-24 2005-03-31 Acadia Pharm Inc Derivados de piperidina n-substituidos como agentes receptores de serotonina.
KR100962972B1 (ko) 2002-07-26 2010-06-09 주식회사유한양행 1-페닐피페리딘-3-온 유도체 및 그의 제조방법
SI2009000T1 (sl) 2003-01-16 2011-09-30 Acadia Pharm Inc Selektivni serotoninski 2A/2C receptorski inverzni agonisti kot terapevtiki za nevrodegenerativne bolezni
US20040192674A1 (en) * 2003-02-14 2004-09-30 Marquis Robert W. Cathepsin L inhibitors
US7384970B2 (en) * 2003-03-24 2008-06-10 Irm Llc Inhibitors of cathepsin S
US7109243B2 (en) * 2003-03-24 2006-09-19 Irm Llc Inhibitors of cathepsin S
US8017791B2 (en) 2003-03-28 2011-09-13 Wayne State University Tri-substituted 2-benzhydryl-5-benzylamino-tetrahydro-pyran-4-ol and 6-benzhydryl-4-benzylamino-tetrahydro-pyran-3-ol analogues, and novel, 3,6-disubstituted pyran derivatives
US7173051B2 (en) * 2003-06-13 2007-02-06 Irm, Llc Inhibitors of cathepsin S
US7256207B2 (en) * 2003-08-20 2007-08-14 Irm Llc Inhibitors of cathepsin S
EP1734948B1 (fr) 2004-04-16 2014-06-11 Wayne State University À trois substitut 2-benzhydryl-5- benzylamino- tétrahydropyran-4-ol et 6-benzhydryl-4-benzylamino-analogues tétrahydropyran-3-ol et nouveaux dérivés pyranne disubstitué 3,6
US20050261278A1 (en) 2004-05-21 2005-11-24 Weiner David M Selective serotonin receptor inverse agonists as therapeutics for disease
US7820695B2 (en) 2004-05-21 2010-10-26 Acadia Pharmaceuticals, Inc. Selective serotonin receptor inverse agonists as therapeutics for disease
EP1796793A4 (fr) * 2004-09-07 2009-08-05 Smithkline Beecham Corp Nouveaux composes
AU2005289444B2 (en) 2004-09-27 2012-06-14 Acadia Pharmaceuticals Inc. Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms
US7790899B2 (en) 2004-09-27 2010-09-07 Acadia Pharmaceuticals, Inc. Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms
JP5254620B2 (ja) 2004-12-03 2013-08-07 メルク・シャープ・アンド・ドーム・コーポレーション Ｃｂ１アンタゴニストとしての置換ピペラジン
MX2008002363A (es) * 2005-08-17 2008-03-18 Schering Corp Ligandos novedosos de cinasa basados en quinolina de alta afinidad.
US8067415B2 (en) * 2005-11-01 2011-11-29 Millennium Pharmaceuticals, Inc. Compounds useful as antagonists of CCR2
WO2007053495A2 (fr) * 2005-11-01 2007-05-10 Millennium Pharmaceuticals, Inc. Composes utiles en tant qu’antagonistes de ccr2
US8067457B2 (en) * 2005-11-01 2011-11-29 Millennium Pharmaceuticals, Inc. Compounds useful as antagonists of CCR2
MX2008009060A (es) * 2006-01-13 2008-09-26 Schering Corp Diaril piperidinas como moduladores de cb1.
JP2009528266A (ja) * 2006-01-18 2009-08-06 シェーリング コーポレイション カンナビノイド受容体修飾因子
US20100179118A1 (en) * 2006-09-08 2010-07-15 Dainippon Sumitomo Pharma Co., Ltd. Cyclic aminoalkylcarboxamide derivative
ES2423485T3 (es) 2007-03-19 2013-09-20 Acadia Pharmaceuticals Inc. Asociaciones de agonistas y antagonistas inversos 5-HT2A con antipsicóticos
WO2008130616A2 (fr) * 2007-04-19 2008-10-30 Schering Corporation Diaryl morpholines comme modulateurs des récepteurs cb1
WO2009005671A2 (fr) * 2007-06-28 2009-01-08 Schering Corporation Pipérazines à substitution servant d'antagonistes des récepteurs cb1
BRPI0814806A2 (pt) * 2007-06-28 2015-02-03 Intervet Int Bv Pirazinas substituídas como antagonistas de cb1
AU2011224417B2 (en) * 2010-03-10 2015-02-19 Janssen Pharmaceutica Nv 4,4-disubstituted piperidine derivatives useful as inhibitors of dipeptidyl peptidase-1 (DPP-1)
US8686152B2 (en) 2010-03-10 2014-04-01 Janssen Pharmaceutica Nv 4,4-disubstituted piperidine derivatives useful as inhibitors of dipeptidyl peptidase-1 (DPP-1)
CU24442B1 (es) 2014-04-04 2019-09-04 X Rx Inc Derivados de n-(1-(espirocíclico)oxo) amida sustituidos como inhibidores de autotaxina
WO2017015272A1 (fr) 2015-07-20 2017-01-26 Acadia Pharmaceuticals Inc. Procédés de préparation de n-(4-fluorobenzyl)-n-(1-méthylpipéridin-4-yl)-n'-(4-2-méthylpropyloxy)phénylméthyl)carbamide, son sel de tartrate et sa forme polymorphe c
WO2017165635A1 (fr) 2016-03-25 2017-09-28 Acadia Pharmaceuticals Inc. Association de pimavansérine et de modulateurs du cytochrome p450
US10953000B2 (en) 2016-03-25 2021-03-23 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome P450 modulators
US11464768B2 (en) 2016-12-20 2022-10-11 Acadia Pharmaceuticals Inc. Pimavanserin alone or in combination for use in the treatment of Alzheimer's disease psychosis
EP3615028A1 (fr) 2017-04-28 2020-03-04 Acadia Pharmaceuticals Inc. Pimavansérine pour le traitement d'un trouble de contrôle des impulsions
WO2019046167A1 (fr) 2017-08-30 2019-03-07 Acadia Pharmaceuticals Inc. Formulations de pimavansérine

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2804416A1 (de) * 1978-02-02 1979-08-09 Boehringer Mannheim Gmbh Neue purin-derivate, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel
ES482439A0 (es) * 1978-07-18 1980-04-01 Hoechst Ag Procedimiento para la preparacion de nuevos derivados de 1-(4-aminopiperidino)-3,4-dihidroisoquinoleina.
US4301151A (en) * 1979-11-27 1981-11-17 Merck & Co., Inc. Long-lasting agonists of enkephalin
US4443461A (en) * 1981-09-10 1984-04-17 John Wyeth & Brother Limited N-[2-[[1-[1H-Indolylalkyl- or oxoalkyl]-4-piperidinyl]-amino]-2-oxoethyl]-arylcarboxamide derivatives
US4680283A (en) * 1984-09-26 1987-07-14 Merck & Co., Inc. Analogs of substance P and eledoisin
DK386089A (da) * 1988-08-12 1990-02-13 Japan Tobacco Inc Katekolderivater
IE903196A1 (en) 1989-09-05 1991-03-13 Searle & Co Substituted n-benzylpiperidine amides
KR920701200A (ko) 1990-03-30 1992-08-11 미즈노 시게루 신규의 4h-3,1-벤조옥사진-4-온 유도체
US5514694A (en) 1992-09-21 1996-05-07 Georgia Tech Research Corp Peptidyl ketoamides
EP0700385A1 (fr) * 1993-05-26 1996-03-13 Smithkline Beecham Laboratoires Pharmaceutiques Nouveaux composes
US5827866A (en) * 1995-06-07 1998-10-27 Ortho Pharmaceutical Corporation Peptidyl heterocycles useful in the treatment of thrombin related disorders
DZ2285A1 (fr) * 1996-08-08 2002-12-25 Smithkline Beecham Corp Inhibiteurs de protéase de la cystéine.

Also Published As

Publication number Publication date
IL131661A0 (en) 2001-01-28
NO995433D0 (no) 1999-11-05
CO4950617A1 (es) 2000-09-01
KR20010012316A (ko) 2001-02-15
EP0991753A1 (fr) 2000-04-12
CA2289010A1 (fr) 1998-11-12
TR199902752T2 (xx) 2000-06-21
AU7288598A (en) 1998-11-27
HUP0001285A2 (hu) 2000-09-28
JP2001525809A (ja) 2001-12-11
BR9808502A (pt) 2000-05-23
CN1255162A (zh) 2000-05-31
PE73799A1 (es) 1999-10-22
EP0991753A4 (fr) 2001-07-11
US6369077B1 (en) 2002-04-09
ZA983843B (en) 1998-11-09
PL336625A1 (en) 2000-07-03
HUP0001285A3 (en) 2000-10-30
WO1998050534A1 (fr) 1998-11-12
MA26494A1 (fr) 2004-12-20

Similar Documents

Publication Publication Date Title
NO995433L (no) Protease-inhibitorer
CA2262668A1 (fr) Inhibiteurs de la cathepsine k
PT87454A (pt) Heterocyclic ketones
WO1996016981A3 (fr) Composes peptidiques pour la prevention et/ou le traitement de maladies induites par no
DE69720773D1 (de) SAUERSTOFF ODER SCHWEFEL ENTHALTENDE 5-GLIEDRIGE HETEROAROMATISHE DERIVATIVE ALS FACTOR Xa HEMMER
LU91069I2 (fr) Aprepitant et ses sels pharmaceutiquement acceptables (EMEND)
ATE334975T1 (de) Sulfonamidderivate, ihre herstellung und verwendung
CA2055670A1 (fr) Composes inhibant la protease des retrovirus
FI915819A0 (fi) Hiv- proteas-inhibitorer.
NO20013254D0 (no) Nye difenylureaforbindelser, fremgangsmåte ved deres fremstilling og farmasöytiske samensetninger som inneholder dem
MY132473A (en) Crystalline hydrochloride of (r)-(-)-2-<n-[4-(1,1- dioxido-3-oxo-2,3-dihydro-benzisothiazol-2-yl)-butyl]-aminomethyl>-chroman
DE60330758D1 (de) Bestimmte pharmazeutisch wertvolle substituierte aminoalkyl-heterocyclen
ID24846A (id) Turunan-turunan bifenilamidina
AP9901578A0 (en) Sulfonylbenzene compounds as anti-inflammatory/analgesic agents.
ATE99934T1 (de) Heteroaryl-3-oxo-propannitril-derivate, nuetzlich zur behandlung von rheumatoider arthritis und anderen autoimmunkrankheiten.
DE69810800D1 (de) Azetidinonderivate zur behandlung von hcmv entzündungen
DK0871626T3 (da) Triazoloner som apolipoprotein-B syntheseinhibitorer
NO20001200L (no) Pyrrolopyrrolonderivater som inhibitorer av nøyrofil elastase
AR043271A1 (es) Compuestos de dihidropironas con heterociclos unidos y su uso en composicines farmaceuticas que poseen actividad inhibidora de hiv proteasa
NO940019L (no) Fremgangsmåte for fremstilling av svovelholdige imidazolderivater
EP0656355A4 (fr) Derive de biphenylmethane et medicament le contenant.
UA26459C2 (uk) Іhгібітор впливу амілоїдhих білків
ATE58135T1 (de) 1,3-oxathianderivate.
ES8201541A1 (es) Un procedimiento para la preparacion de nuevas guanilamidi- nas
JPS6422898A (en) 2-alanyl-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid derivative

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application